Renal Cell Carcinoma Perspective

 
 
  • The Future of Cancer Drugs: RNA Therapies, Bacteria, and Viruses Several new classes of anti-cancer therapies are in development with the hope of becoming the next major advance in oncology.
  • New Therapies Take Aim at Brain Metastasis   Emerging research is uncovering new treatment options for brain metastasis, a common and dire consequence of many cancers. Dr Matthias Preusser highlights the latest findings from ESMO 2016.
  • Top News From ESMO 2016: Slideshow Practice-changing research in lung cancer; colorectal cancer; and breast, ovarian, and kidney cancer featured prominently at this year's congress.
  • A New Oncology Target: The Heart Delivering the most effective dose of chemotherapy without causing cardiotoxicity is a key goal of the emerging field of cardio-oncology. But are the current predictors of cardiotoxic risk adequate?
  • Is Immunotherapy Safe for Older Melanoma Patients?   How do adverse events from immunotherapy compare in younger vs older patients? Dr Weber comments on the safety of checkpoint inhibitors for our older patients.
  • Rethinking Cytoreductive Nephrectomy in Metastatic RCC Recent data suggest that cytoreductive nephrectomy may confer a significant survival advantage in metastatic renal cell carcinoma.
  • #ASCO16: Hot Topics on Twitter Social media activity using #ASCO16 at the ASCO annual meeting achieved record-breaking highs in many categories.
  • Cabozantinib a Possible New Standard in Second-line Metastatic RCC   Dr David Graham reviews the METEOR trial in metastatic renal cell carcinoma, one of the most important studies on genitourinary malignancies presented at ASCO 2016.
  • 'Think Different' About Clinical Cancer Research In the wake of Vice President Biden's talk at ASCO 2016, Dr David Graham suggests a new approach to collect data at the point of care to guide future clinical cancer treatments.
  • What to Watch for in Genitourinary Cancers This year's ASCO annual meeting will feature important developments in bladder cancer, renal cell carcinoma, and prostate cancer.
  • PD-1 Inhibitors Show Promise in Upper GI Cancers Early findings suggest that immunotherapies, such as PD-1 inhibitors, could play a large role in the management of upper GI cancers, as reported by Dr Brandon Smaglo from GISC 2016.
  • Genitourinary Cancers Symposium (GUCS) 2016 Read clinically focused news coverage of key developments from GUCS 2016.
  • Pembrolizumab Shows Durable Responses in TNBC   Single-agent PD-L1 antibodies in triple-negative breast cancer show exceptionally durable responses, raising hope for stronger responses with combination therapies, says Dr Hope Rugo from SABCS 2015.
  • Quiz: The Alcohol-Cancer Connection How much do you know about the link between alcohol and cancer and how this influences advice to patients?
  • 14th International Kidney Cancer Symposium (IKCS) Read clinically focused news coverage of key developments from IKCS 2015.
  • Patient Advocates Emerge as Key Stakeholders   Patient advocates have emerged as sophisticated stakeholders who understand the healthcare system and are knowledgeable about pertinent scientific developments in their disease area.
  • A Look at the Evidence: Diet, Exercise and Cancer Risk How much do diet and exercise affect cancer risk? At the ASCO 2015 annual meeting, an expert in cancer prevention discusses the weight of the evidence.
  • HBV: React Before the Virus Does This once-fatal condition can now be easily prevented, but to screen patients appropriately requires a level of awareness that is lacking at present.
  • The Patient as Research Partner Oncologists recall the critical role that patients have played in their research and clinical knowledge.
  • Recognize and Treat TKI-Induced Toxic Skin Effects Dr Graeme M. Lipper reviews a study that examined the prevalence and clinical spectrum of adverse skin reactions in patients treated with the chemotherapy drug cabozantinib.
Купить Левитра 60 мг

comprar viagra sin receta

farm-pump-ua.com/deka-durabolin.html